Abilify “Dear Doctor” letter
Executive Summary
Bristol-Myers Squibb's March 25 "Dear Doctor" 1letter on the atypical antipsychotic class warning for diabetes says "an exhaustive review of the Abilify database revealed no increased signal for diabetes," although "additional information is needed to confirm this." Bristol and Otsuka updated Abilify (aripiprazole) labeling in March to reflect FDA's requested class warning (2"The Pink Sheet" April 5, 2004, p. 32)...